CME Information

Target Audience

This activity is designed for specialists in endocrinology and primary care.

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Describe the multiple metabolic defects that occur in T2DM.
• Identify at-risk patients in various populations, including adolescents.
• Detail the differences in risk of T2DM; define possible subtypes of T2DM and its complications based on ethnicity.
• Discuss the controversy surrounding glycemic control targets.
• Summarize the effects of GLP-1 and GLP-1 receptor agonists on metabolism.
• Describe the role of pancreatic transplantation in DM management.
• Explain how to evaluate and treat inpatient hyperglycemia.
• Use peer-to-peer interactions to maximize the effectiveness of treatment.
• Recognize the role of psychosocial barriers in patients with DM.

Release Date: June 1, 2009.
Valid for credit through May 31, 2010.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Indiana University School of Medicine and Health Focus, Inc. Indiana University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Indiana University School of Medicine designates this educational activity for a maximum of 7.0 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

To receive credit, participants must view the presentation slides and listen to the audio recordings, and complete the posttest (passing score = 70% or higher) and evaluation form. Receive a CME certificate, please download

Length of time to complete the activity: 7.0 hours.

Disclosure Information

Commercial Support

Indiana University School of Medicine and Health Focus, Inc. gratefully acknowledge the unrestricted educational grant provided by Merck & Co., Inc., and Novo Nordisk.

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. Dr. D’Alessio disclosed that he is a paid consultant for Merck, Johnson & Johnson, Takeda, Wyeth, and Amylin. He also receives research grant monies from Lilly, Amylin, and Ethicon. Dr. Duckworth disclosed that he receives grant support from Roche Diagnostics. He is also a paid consultant for Novo and Caremark. He also previously received speaker honoraria form Medcon. Dr. Gill disclosed that he is on the speaker’s bureau and has previously received speaker honoraria from Merck and Takeda. Dr. Juneja disclosed that he is a paid consultant and receives research grant monies from Sanofi-aventis. He also previously received speaker honoraria from Merck and Eli Lilly/Amylin. Diabetes Innovations compensates Dr. Juneja with royalty payments for the sale of CGS. Drs. Clark, Fridell, and Johns reported that they have no actual or potential conflict of interest in regard to this activity.

NOTICE: The Indiana University School of Medicine advises the participant that this CME activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.